RT Journal Article
SR Electronic
T1 Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20040675
DO 10.1101/2020.03.23.20040675
A1 Xiaofeng Yang
A1 Tongxin Dai
A1 Xiaobo Zhou
A1 Hongbo Qian
A1 Rui Guo
A1 Lei Lei
A1 Xingzhe Zhang
A1 Dan Zhang
A1 Lin Shi
A1 Yanbin Cheng
A1 Jinsong Hu
A1 Yaling Guo
A1 Baojun Zhang
YR 2020
UL http://medrxiv.org/content/early/2020/12/21/2020.03.23.20040675.abstract
AB Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to most of countries in the world, threatening the health and lives of many people. Unfortunately, information regarding the immunological characteristics in COVID-19 patients remains limited. Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in the adaptive immune cell populations and phenotypes. In comparison to HD, the lymphocyte percentage was slightly decreased, the percentages of CD4 and CD8 T cells in lymphocytes are similar, whereas B cell percentage increased in COVID-19 patients. T cells, especially CD8 T cells, showed an enhanced expression of late activation marker CD25 and exhaustion marker PD-1. Importantly, SARS-CoV-2 induced an increased percentage of T follicular helpher (Tfh)- and germinal center B-like (GCB-like) cells in the blood. However, the parameters in COVD-19 patients remained unchanged across various age groups. Therefore, we demonstrated that the T and B cells can be activated normally and exhibit functional features. These data provide a clue that the adaptive immunity in most people could be primed to induce a significant immune response against SARS-CoV-2 infection upon receiving standard medical care.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCOVID-19 infection was excluded from clinical trial registrition.Funding StatementThis work was supported by grants from Natural Science Foundation of China (No. 81820108017), Natural Science Foundation of China (No. 81771673), and COVID-19 special project of Xi'an Jiaotong University Foundation (xzy032020002). We thank all the doctors, nurses, public health workers, and patients for their contribution against SARS-CoV-2 infection.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available in the manuscript.